株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のインフルエンザ市場

The Global Influenza Market

発行 BCC Research 商品コード 99390
出版日 ページ情報 英文 191 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.16円で換算しております。
Back to Top
世界のインフルエンザ市場 The Global Influenza Market
出版日: 2017年03月23日 ページ情報: 英文 191 Pages
概要

世界のインフルエンザ市場は、2016年の54億米ドルから、2021年には64億米ドルまで拡大すると見られています。市場は、2016年〜2021年のCAGR (複合年間成長率) で、3.6%の成長が予測されています。

当レポートでは、世界のインフルエンザ市場について調査分析し、市場概要、市場動向と予測、製品情報、政府の取り組み、市場力学、主要企業プロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 産業概要

  • 定義
  • 市場の歴史
    • エピデミック/パンデミック
    • ウイルスの変異
    • インフルエンザの種類
    • インフルエンザウイルスの世界の活動
  • WHO (世界保健機関) とCDC (疾病対策予防センター) :インフルエンザへの反応
  • 米国のウイルスの監視
  • FDAによるワクチンと関連する生物学的製剤
  • 推奨ワクチン
  • 月齢
  • ワクチンの有効性
  • 人口統計とインフルエンザの発症/死亡率
  • ルエンザによる死亡

第4章 市場に影響を与える問題点

  • H1N1の大流行 (豚インフルエンザ)
  • 国際的なインフルエンザワクチンの備蓄
  • 抗ウイルス耐性
  • 再生ウイルス
  • マスコミ報道と予防接種
  • 流行/パンデミックの脅威
  • パンデミックに対する準備計画
  • 赤外線センサーと熱探知カメラ
  • 米国
  • 日本
  • 中国
  • ブラジル
  • 英国
  • 世界のインフルエンザの影響

第5章 特許分析

  • 概要
  • インフルエンザ特許:特許番号別
  • EMORY UNIVERSITY
  • GLAXOSMITHKLINE BIOLOGICALS SA
  • LONGHORN VACCINES AND DIAGNOSTICS LLC
  • NOVARTIS
  • NOVAVAX
  • 塩野義製薬
  • ST. JUDE CHILDREN'S RESEARCH HOSPITAL
  • U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
  • UNIVERSITY OF PENNSYLVANIA
  • VERTEX PHARMACEUTICALS INC.
  • WISCONSIN ALUMNI RESEARCH FOUNDATION

第6章 インフルエンザワクチン

  • 概要
  • 現在のワクチン
  • ワクチン開発

第7章 インフルエンザ治療

  • 概要
  • 現在の治療
  • インフルエンザ治療の発展
  • 世界のインフルエンザ治療市場
  • 地域別市場のサマリー
  • 競合企業分析

第8章 インフルエンザ診断

  • 概要
  • 検査内容
  • 製品説明
  • ラボラトリーサービス
  • 地域別市場のサマリー
  • 競合企業分析

第9章 インフルエンザ市場のサマリー

  • インフルエンザ市場動向の概要
  • 総合市場分析
  • 地域別市場のサマリー

第10章 企業プロファイル

  • 重要な企業買収
  • ALERE INC.
  • ASTRAZENECA/MEDIMMUNE
  • BECTON DICKINSON AND COMPANY
  • CEPHEID
  • 第一三共
  • GLAXOSMITHKLINE PLC
  • HOLOGIC INC.
  • 田辺三菱製薬
  • MYLAN N.V.
  • ORASURE TECHNOLOGIES
  • PROTEIN SCIENCES CORPORATION
  • QIAGEN N.V.
  • QUIDEL CORP.
  • ROCHE LTD.
  • SANOFI/SANOFI PASTEUR
  • SEKISUI DIAGNOSTICS LLC
  • SEQIRUS CSL LIMITED

第11章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM049D

Report Highlights

The global influenza reached $5.1 billion in 2015. This market is expected to increase from $5.4 billion in 2016 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 3.6% for 2016-2021.

Report Includes:

  • An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
  • Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
  • Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
  • Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities.
  • Profiles of major players in the industry.

Report Scope

This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.

Analyst Credentials

Melissa Elder is an experienced healthcare market analyst specializing in medical treatments, equipment and devices. Ms. Elder holds a B.S. in Business Management and is currently working to complete her M.B.A. in Health Care Management. Ms. Elder has been involved in the healthcare industry since 1996, providing more than 20 years of industry expertise. She has specialized in market research for the past 18 years, focusing on the areas of advanced medical technologies, biological products and animal health. In depth analysis into more than 100 health-related topics has given Ms. Elder substantial insight into industry dynamics, market influences and future direction of various health markets. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare specialties. She has authored several industry specific documents and is a well-respected contributor to the market research community. Her writings are published in magazines, newspapers and professional journals. She is also an experienced custom market research writer who has worked with a large variety of clients in many fields who require innumerable variations to research documents.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY
    • SUMMARY TABLE: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 ($ MILLIONS)
    • SUMMARY FIGURE: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 ($ MILLIONS)

CHAPTER 3 - INDUSTRY OVERVIEW

  • OVERVIEW
  • HISTORY OF THE MARKET
    • EPIDEMICS/PANDEMICS
      • Spanish Influenza 1918--1919
      • Hong Kong Influenza 1968
      • Asian Influenza 1957
      • Swine Flu 1976
      • Russian Influenza 1977
      • Avian Flu 1961, 1997, 2003-2009/2010 (sporadic)
      • Novel Influenza H1N1 2009
        • TABLE 1: DISTRIBUTION OF FATAL CASES OF H1N1 PANDEMIC BY WHO REGIONS, 2009-2010
      • CDC Reported 2009 H1N1 Cases in the U.S.
        • TABLE 2: CDC ESTIMATES OF 2009 H1N1 CASES AND RELATED HOSPITALIZATIONS AND DEATHS, BY AGE GROUP, APRIL 2009 - MARCH 13, 2010
      • Influenza H7N9 2013
        • TABLE 3: CUMULATIVE NUMBER OF CONFIRMED CASES OF H7N9, BY REGION, OCTOBER 2016
    • VIRUS MUTATIONS
    • TYPES OF INFLUENZA
      • Influenza Type A
      • Influenza Type B
      • Influenza Type C
    • WORLD ACTIVITY OF INFLUENZA VIRUSES
      • FIGURE 1: WORLDWIDE INFLUENZA ACTIVITY OCTOBER 2014 - MAY 2015
      • FIGURE 2: WORLDWIDE INFLUENZA ACTIVITY MAY 2015 - SEPTEMBER 2015
  • THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE
    • WORLD HEALTH ORGANIZATION
    • CENTERS FOR DISEASE CONTROL AND PREVENTION
  • U.S. VIRAL SURVEILLANCE
    • TABLE 4: VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)
    • FIGURE 3: VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)
  • FDA'S VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE AND VACCINE COMPOSITION
    • TABLE 5: INFLUENZA VIRUS RECOMMENDATIONS FOR U.S. INFLUENZA SEASONS, 2003-2017
  • VACCINE RECOMMENDATIONS
    • TABLE 6: THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)
    • TABLE 7: CDC INFLUENZA VACCINE RECOMMENDATIONS FOR ALL PEOPLE FROM
  • MONTHS OF AGE
    • FIGURE 4: RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS ALLERGIC TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES FOR U.S. INFLUENZA SEASON, 2015-2016
  • VACCINE EFFECTIVENESS
    • TABLE 8: ADJUSTED VACCINE EFFECTIVENESS ESTIMATES FOR INFLUENZA SEASONS, 2005-2016
    • UNIVERSAL VACCINE
    • INFLUENZA PREPAREDNESS AND RAPID PRODUCTION
  • POPULATION DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY
    • GLOBAL DEMOGRAPHICS
      • TABLE 9: GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)
      • FIGURE 5: GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)
      • TABLE 10: GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)
      • FIGURE 6: GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)
      • TABLE 11: GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2020
      • FIGURE 7: GLOBAL POPULATION BY SELECTED COUNTRY, 2010- 2020 (MILLIONS)
    • GLOBAL LIFE EXPECTANCY
      • TABLE 12: GLOBAL LIFE EXPECTANCY AT BIRTH, BY SELECTED COUNTRY, 1980-2020 (YEARS)
      • FIGURE 8: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2020 (YEARS)
    • INFLUENZA INCIDENCE AND MORTALITY
      • TABLE 13: IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP, APRIL 2009-2010

CHAPTER 4 - ISSUES AFFECTING THE MARKET

  • H1N1 OUTBREAK 2009 (SWINE FLU)
    • RAPID DIAGNOSTICS
      • Pandemic Testing
      • Seasonal Influenza Tests
    • AVIAN FLU
      • TABLE 14: COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS
    • AVIAN FLU SURVEILLANCE
      • TABLE 15: WHO-REPORTED CASES OF AVIAN INFLUENZA A/ (H5N1) IN HUMANS
      • FIGURE 9: WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS, 2003-2016* (NO.)
      • The WHO and Containment for Pandemic Influenza
        • FIGURE 10: APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)
  • INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS
    • PRE-PANDEMIC VACCINATION
      • FIGURE 11: TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS FOR SELECTED COUNTRIES (MILLION)
      • Biomedical Advanced Research and Development Authority (BARDA)
  • ANTIVIRAL RESISTANCE
  • RECREATED VIRUSES
  • IMMATERIALIZED MARKET RISK
  • MEDIA COVERAGE AND VACCINATIONS
  • EPIDEMIC/PANDEMIC THREAT
    • TABLE 16: ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA, SEVERE OUTBREAKS BASED ON 2017-PROJECTED POPULATION (U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES) (THOUSANDS)
  • PANDEMIC PREPAREDNESS PLANS
    • TABLE 17: ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN
  • INFRARED SENSORS AND THERMAL IMAGERS
  • THE UNITED STATES
  • JAPAN
    • TABLE 18: OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS
  • CHINA
    • TABLE 19: CHINA'S INFLUENZA PANDEMIC WARNING LEVELS
  • BRAZIL
    • TABLE 20: BRAZIL'S INFLUENZA PANDEMIC WARNING LEVELS AND ACTION
  • UNITED KINGDOM
  • WORLD INFLUENZA IMPACT

CHAPTER 5 - PATENT ANALYSIS

  • OVERVIEW
  • INFLUENZA PATENTS BY PATENT NUMBER
    • TABLE 21: PATENTS FOR INFLUENZA, BY YEAR ISSUED, 2002-2016
    • FIGURE 12: PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2016
    • TABLE 22: RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY, BY PATENT NUMBER
    • TABLE 23: NUMBER OF U.S. PATENTS BY INFLUENZA MARKET COMPETITOR
  • EMORY UNIVERSITY
  • GLAXOSMITHKLINE BIOLOGICALS SA
  • LONGHORN VACCINES AND DIAGNOSTICS LLC
  • NOVARTIS
  • NOVAVAX
  • SHIONOGI & CO. LTD.
  • ST. JUDE CHILDREN'S RESEARCH HOSPITAL
  • U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
  • UNIVERSITY OF PENNSYLVANIA
  • VERTEX PHARMACEUTICALS INC.
  • WISCONSIN ALUMNI RESEARCH FOUNDATION

CHAPTER 6 - INFLUENZA VACCINES

  • OVERVIEW
    • HISTORY OF VACCINE MANUFACTURER PARTICIPATION IN THE U.S.
      • TABLE 24: INFLUENZA VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2017
  • CURRENT VACCINES
    • ASTRAZENECA - MEDIMMUNE
    • SEQIRUS - CSL
    • GLAXOSMITHKLINE
    • MYLAN
    • NANOTHERAPEUTICS
    • PROTEIN SCIENCES CORP.
    • SANOFI PASTEUR
    • SINOVAC BIOTECH
      • TABLE 25: EXAMPLES OF MARKETED SEASONAL INFLUENZA VACCINE PRODUCTS
    • SEASONAL 2016-2017 VACCINE APPROVALS BY FDA
      • TABLE 26: SEASONAL INFLUENZA VACCINE FDA APPROVALS BASED ON ADULT DOSAGE, 2016-2017
    • PANDEMIC INFLUENZA VACCINES
      • TABLE 27: EXAMPLES OF APPROVED PANDEMIC INFLUENZA VACCINE PRODUCTS
  • VACCINE DEVELOPMENTS
    • CLINICAL TRIALS
      • TABLE 28: CLINICAL TRIALS FOR INFLUENZA PREVENTION (VACCINES AND BIOLOGICS) BY SELECTED COUNTRY AND TRIAL STATUS
    • BIKEN
      • TABLE 29: BIKEN INFLUENZA VACCINE PIPELINE
      • BiondVax Pharmaceuticals
        • TABLE 30: BIONDVAX PHARMACEUTICALS INFLUENZA VACCINE PIPELINE
      • Changchun BCHT Biotechnology Co.
        • TABLE 31: CHANGCHUN BCHT BIOTECHNOLOGY INFLUENZA VACCINE PIPELINE
      • Eurocine Vaccines AB
        • TABLE 32: EUROCINE VACCINES INFLUENZA VACCINE PIPELINE
      • Institute of Vaccines and Medical Biologicals, Vietnam
        • TABLE 33: INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS, VIETNAM INFLUENZA VACCINE PIPELINE
      • Longeveron LLC
        • TABLE 34: LONGEVERON LLC INFLUENZA VACCINE PIPELINE
      • MedImmune
        • TABLE 35 MEDIMMUNE INFLUENZA VACCINE PIPELINE
      • Mitsubishi Tanabe
        • TABLE 36: MITSUBISHI TANABE'S INFLUENZA VACCINE PIPELINE
      • NanoBio Corp.
        • TABLE 37: NANOBIO CORP. INFLUENZA VACCINE PIPELINE
      • Nanotherapeutics Inc.
        • TABLE 38: NANOTHERAPEUTICS' INFLUENZA VACCINE PIPELINE
      • NanoViricides Inc.
        • TABLE 39: NANOVIRICIDES INFLUENZA VACCINE PIPELINE
      • NexBio Inc.
        • TABLE 40: NEXBIO CORPORATION INFLUENZA VACCINE PIPELINE
      • Nitto Denko Corporation
        • TABLE 41: NITTO DENKO CORPORATION INFLUENZA VACCINE PIPELINE
      • Novavax, Inc.
        • TABLE 42: NOVAVAX INFLUENZA VACCINE PIPELINE
      • Pantec Biosolutions AG
      • PaxVax Corp.
        • TABLE 43: PAXVAX CORPORATION INFLUENZA VACCINE PIPELINE
      • PepTcell Limited
        • TABLE 44: PEPTCELL LTD. INFLUENZA VACCINE PIPELINE
      • Protein Sciences Corp.
        • TABLE 45: PROTEIN SCIENCES INFLUENZA VACCINE PIPELINE
      • Sanofi Pasteur
        • TABLE 46: SANOFI PASTEUR INFLUENZA VACCINE PIPELINE
      • Seqirus
        • TABLE 47: SEQIRUS INFLUENZA VACCINE PIPELINE
      • Vaxart Inc.
        • TABLE 48: VAXART INFLUENZA VACCINE PIPELINE
    • THE GLOBAL INFLUENZA VACCINE MARKET
      • TABLE 49: GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
      • FIGURE 13: GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
      • Seasonal vs. Pandemic Sales
        • FIGURE 14: GLOBAL MARKET FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2016 ($ MILLIONS)
    • REGIONAL MARKET SUMMARY
      • TABLE 50: GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 15: GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, 2010-2021 ($ MILLIONS)
      • FIGURE 16: DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES, BY REGION, 2016 (%)
      • The U.S. Influenza Vaccine Market
        • TABLE 51: U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
        • FIGURE 17: U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2021 ($ MILLIONS)
        • TABLE 52: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S., BY SEASON, 2005-2017
        • FIGURE 18: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2017 (MILLIONS)
        • TABLE 53: UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S., BY MANUFACTURER, 2016-2017 (UNITS PER MILLION/%)
      • The European Influenza Vaccine Market
        • TABLE 54: ESTIMATED INFLUENZA VACCINE SALES DISTRIBUTION IN EU, BY COUNTRY, 2016-2017 (%)
        • TABLE 55: EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
        • FIGURE 19: EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
    • GLOBAL COMPETITOR ANALYSIS
      • TABLE 56: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013-2016 (%)
      • FIGURE 20: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013 (%)
      • FIGURE 21: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2014 (%)
      • FIGURE 22: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2015 (%)
      • FIGURE 23: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2016 (%)

CHAPTER 7 - INFLUENZA THERAPIES

  • OVERVIEW
  • CURRENT THERAPIES
    • DAIICHI SANKYO
    • GLAXOSMITHKLINE
    • ROCHE
    • BIOCRYST PHARMACEUTICALS/SEQIRUS
    • OTHERS
      • TABLE 57: MARKETED THERAPIES, BY COMPANY, 2016
    • GENERIC AVAILABILITY
      • TABLE 58: GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS
  • INFLUENZA TREATMENT DEVELOPMENTS
    • CLINICAL TRIALS
      • TABLE 59: CLINICAL TRIALS FOR INFLUENZA THERAPEUTICS, BY SELECTED COUNTRY AND TRIAL STATUS
    • Amarillo Biosciences Inc.
      • TABLE 60: AMARILLO BIOSCIENCES INFLUENZA TREATMENT PIPELINE
    • AstraZeneca (MedImmune)
      • TABLE 61: ASTRAZENECA INFLUENZA TREATMENT PIPELINE
    • Genentech
      • TABLE 62: GENENTECH INFLUENZA TREATMENT PIPELINE
    • GlaxoSmithKline
      • TABLE 63: GLAXOSMITHKLINE INFLUENZA TREATMENT PIPELINE
    • Hemispherx Biopharma
      • TABLE 64: HEMISPHERX BIOPHARMA INFLUENZA TREATMENT PIPELINE
    • Il-Yang Pharm
      • TABLE 65: IL-YANG INFLUENZA TREATMENT PIPELINE
    • Janssen Pharmaceutical Company
      • TABLE 66: JANSSEN PHARMACEUTICAL CO. INFLUENZA TREATMENT PIPELINE
    • Materia Medica Holding
      • TABLE 67: MATERIA MEDICA INFLUENZA TREATMENT PIPELINE
    • Romark Laboratories
      • TABLE 68: ROMARK LABORATORIES INFLUENZA TREATMENT PIPELINE
    • Sarepta Therapeutics
      • TABLE 69: SAREPTA THERAPEUTICS INFLUENZA TREATMENT PIPELINE
    • Shionogi
      • TABLE 70: SHIONOGI INFLUENZA TREATMENT PIPELINE
    • Toyama Chemical
      • TABLE 71: TOYAMA CHEMICAL INFLUENZA TREATMENT PIPELINE
    • Visterra Inc.
      • TABLE 72: VISTERRA INFLUENZA TREATMENT PIPELINE
  • THE GLOBAL INFLUENZA THERAPEUTICS MARKET
    • TABLE 73: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
    • FIGURE 24: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
  • REGIONAL MARKET SUMMARY
    • TABLE 74: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 25: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, 2010-2021 ($ MILLIONS)
    • FIGURE 26: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES, BY REGION, 2016 (%)
  • COMPETITOR ANALYSIS
    • TABLE 75: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013-2016 (%)
    • FIGURE 27: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013 (%)
    • FIGURE 28: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2014 (%)
    • FIGURE 29: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2015 (%)
    • FIGURE 30: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2016 (%)

CHAPTER 8 - INFLUENZA DIAGNOSTICS

  • OVERVIEW
    • TABLE 76: INFLUENZA DIAGNOSTIC TABLE
  • TEST DESCRIPTIONS[2]
    • Viral Culture
    • Rapid Influenza Diagnostic Tests
      • TABLE 77: CLINICAL CONSIDERATIONS OF RAPID TESTING DURING HIGH INFLUENZA PREVALENCE
      • TABLE 78: CLINICAL CONSIDERATIONS OF RAPID TESTING DURING LOW INFLUENZA PREVALENCE
    • Serologic Testing
  • PRODUCT DESCRIPTION
    • Alere
    • Becton Dickinson
    • BTNX Inc.
    • Cepheid
    • Hologic Inc.
    • Luminex Corp.
    • Meridian Biosciences Inc.
    • OraSure Technologies
    • Qiagen
    • Quidel Corp.
    • Remel Inc. (Thermo Scientific)
    • Response Biomedical Corp.
    • SA Scientific Ltd.
    • Sekisui Diagnostics
    • Thermo Fisher Scientific
      • TABLE 79: SELECTED MARKETED RAPID TEST PRODUCTS, DECEMBER 2016
      • TABLE 80: AVERAGE PRICE OF SELECTED RAPID INFLUENZA TESTS ($)
  • LABORATORY SERVICES
    • Associated Regional University Pathologists (ARUP) Laboratories
    • Bio-Reference Laboratories Inc.
    • Laboratory Corp. of America
    • Pathology Associates Medical Laboratories
    • Quest Diagnostics
      • TABLE 81: PROVIDERS OF TEST SERVICES
  • MARKET ANALYSIS
    • TABLE 82: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 31: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, 2010-2021 ($ MILLIONS)
    • FIGURE 32: DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY PRODUCT CLASSIFICATION, 2016 (%)
    • FIGURE 33: DISTRIBUTION OF CONVENTIONAL LABORATORY INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)
    • FIGURE 34: DISTRIBUTION OF RAPID INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)
  • REGIONAL MARKET SUMMARY
    • TABLE 83: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 35: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, 2010-2021 ($ MILLIONS)
    • FIGURE 36: DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2016 (%)
    • TABLE 84: NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*
    • FIGURE 37: NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*
  • COMPETITOR ANALYSIS
    • TABLE 85: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013-2016 (%)
    • FIGURE 38: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013 (%)
    • FIGURE 39: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2014 (%)
    • FIGURE 40: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2015 (%)
    • FIGURE 41: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2016 (%)

CHAPTER 9 - INFLUENZA MARKET SUMMARY

  • OVERVIEW OF INFLUENZA MARKET TRENDS
    • TABLE 86: INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS
    • TABLE 87: INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS
    • TABLE 88: INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS
  • TOTAL MARKET ANALYSIS
    • TABLE 89: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 42: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 ($ MILLIONS)
    • FIGURE 43: DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2016 (%)
  • REGIONAL MARKET SUMMARY
    • TABLE 90: GLOBAL INFLUENZA MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 44: GLOBAL INFLUENZA MARKET, BY REGION, 2010-2021 ($ MILLIONS)
    • FIGURE 45: DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REGION, 2016 (%)

CHAPTER 10 - COMPANY PROFILES

  • SIGNIFICANT COMPANY ACQUISITIONS
  • ALERE INC.
    • TABLE 91: ALERE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 46: ALERE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • ASTRAZENECA/MEDIMMUNE
    • TABLE 92: ASTRAZENECA'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 47: ASTRAZENECA'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • BECTON DICKINSON AND COMPANY
    • TABLE 93: BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 48: BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • CEPHEID
    • TABLE 94: DANAHER'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 49: DANAHER'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • DAIICHI SANKYO
    • TABLE 95: DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 50: DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • GLAXOSMITHKLINE PLC
    • TABLE 96: GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 51: GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • HOLOGIC INC.
    • TABLE 97: HOLOGIC'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 52: HOLOGIC'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • MITSUBISHI TANABE PHARMA CORP.
    • TABLE 98: MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 53: MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • MYLAN N.V.
    • TABLE 99: MYLAN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 54: MYLAN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • ORASURE TECHNOLOGIES
    • TABLE 100: ORASURE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 55: ORASURE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • PROTEIN SCIENCES CORPORATION
  • QIAGEN N.V.
    • TABLE 101: QIAGEN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 56: QIAGEN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • QUIDEL CORP.
    • TABLE 102: QUIDEL'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 57: QUIDEL'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • ROCHE LTD.
    • TABLE 103: ROCHE GROUP'S REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 58: ROCHE GROUP'S REVENUES, 2013-2016 ($ MILLIONS)
  • SANOFI/SANOFI PASTEUR
    • TABLE 104: SANOFI'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 59: SANOFI'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
  • SEKISUI DIAGNOSTICS LLC
    • TABLE 105: SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* ($ BILLIONS)
    • FIGURE 60: SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* ($ BILLIONS)
  • SEQIRUS CSL LIMITED
    • TABLE 106: CSL LIMITED'S COMPANY REVENUES, 2013-2016* ($ MILLIONS)
    • FIGURE 61: CSL LIMITED'S COMPANY REVENUES, 2013-2016* ($ MILLIONS)

CHAPTER 11 - APPENDICES

  • APPENDIX I
    • MANUFACTURERS AND DEVELOPERS
  • APPENDIX II
    • TABLE 107: APPROVED WHO INFLUENZA CENTERS BY REGION
  • APPENDIX III
    • GLOSSARY OF TERMS[3]
    • LIST OF ACRONYMS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: DISTRIBUTION OF FATAL CASES OF H1N1 PANDEMIC BY WHO REGIONS, 2009-2010
    • TABLE 2: CDC ESTIMATES OF 2009 H1N1 CASES AND RELATED HOSPITALIZATIONS AND DEATHS, BY AGE GROUP, APRIL 2009 - MARCH 13, 2010
    • TABLE 3: CUMULATIVE NUMBER OF CONFIRMED CASES OF H7N9, BY REGION, OCTOBER 2016
    • TABLE 4: VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)
    • TABLE 5: INFLUENZA VIRUS RECOMMENDATIONS FOR U.S. INFLUENZA SEASONS, 2003-2017
    • TABLE 6: THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)
    • TABLE 7: CDC INFLUENZA VACCINE RECOMMENDATIONS FOR ALL PEOPLE FROM 6 MONTHS OF AGE
    • TABLE 8: ADJUSTED VACCINE EFFECTIVENESS ESTIMATES FOR INFLUENZA SEASONS, 2005-2016
    • TABLE 9: GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)
    • TABLE 10: GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)
    • TABLE 11: GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2020
    • TABLE 12: GLOBAL LIFE EXPECTANCY AT BIRTH, BY SELECTED COUNTRY, 1980-2020 (YEARS)
    • TABLE 13: IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP, APRIL 2009-2010
    • TABLE 14: COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS
    • TABLE 15: WHO-REPORTED CASES OF AVIAN INFLUENZA A/ (H5N1) IN HUMANS
    • TABLE 16: ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA, SEVERE OUTBREAKS BASED ON 2017-PROJECTED POPULATION (U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES) (THOUSANDS)
    • TABLE 17: ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN
    • TABLE 18: OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS
    • TABLE 19: CHINA'S INFLUENZA PANDEMIC WARNING LEVELS
    • TABLE 20: BRAZIL'S INFLUENZA PANDEMIC WARNING LEVELS AND ACTION
    • TABLE 21: PATENTS FOR INFLUENZA, BY YEAR ISSUED, 2002-2016
    • TABLE 22: RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY, BY PATENT NUMBER
    • TABLE 23: NUMBER OF U.S. PATENTS BY INFLUENZA MARKET COMPETITOR
    • TABLE 24: INFLUENZA VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2017
    • TABLE 25: EXAMPLES OF MARKETED SEASONAL INFLUENZA VACCINE PRODUCTS
    • TABLE 26: SEASONAL INFLUENZA VACCINE FDA APPROVALS BASED ON ADULT DOSAGE, 2016-2017
    • TABLE 27: EXAMPLES OF APPROVED PANDEMIC INFLUENZA VACCINE PRODUCTS
    • TABLE 28: CLINICAL TRIALS FOR INFLUENZA PREVENTION (VACCINES AND BIOLOGICS) BY SELECTED COUNTRY AND TRIAL STATUS
    • TABLE 29: BIKEN INFLUENZA VACCINE PIPELINE
    • TABLE 30: BIONDVAX PHARMACEUTICALS INFLUENZA VACCINE PIPELINE
    • TABLE 31: CHANGCHUN BCHT BIOTECHNOLOGY INFLUENZA VACCINE PIPELINE
    • TABLE 32: EUROCINE VACCINES INFLUENZA VACCINE PIPELINE
    • TABLE 33: INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS, VIETNAM INFLUENZA VACCINE PIPELINE
    • TABLE 34: LONGEVERON LLC INFLUENZA VACCINE PIPELINE
    • TABLE 35: MEDIMMUNE INFLUENZA VACCINE PIPELINE
    • TABLE 36: MITSUBISHI TANABE'S INFLUENZA VACCINE PIPELINE
    • TABLE 37: NANOBIO CORP. INFLUENZA VACCINE PIPELINE
    • TABLE 38: NANOTHERAPEUTICS' INFLUENZA VACCINE PIPELINE
    • TABLE 39: NANOVIRICIDES INFLUENZA VACCINE PIPELINE
    • TABLE 40: NEXBIO CORPORATION INFLUENZA VACCINE PIPELINE
    • TABLE 41: NITTO DENKO CORPORATION INFLUENZA VACCINE PIPELINE
    • TABLE 42: NOVAVAX INFLUENZA VACCINE PIPELINE
    • TABLE 43: PAXVAX CORPORATION INFLUENZA VACCINE PIPELINE
    • TABLE 44: PEPTCELL LTD. INFLUENZA VACCINE PIPELINE
    • TABLE 45: PROTEIN SCIENCES INFLUENZA VACCINE PIPELINE
    • TABLE 46: SANOFI PASTEUR INFLUENZA VACCINE PIPELINE
    • TABLE 47: SEQIRUS INFLUENZA VACCINE PIPELINE
    • TABLE 48: VAXART INFLUENZA VACCINE PIPELINE
    • TABLE 49: GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
    • TABLE 50: GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 51: U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
    • TABLE 52: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S., BY SEASON, 2005-2017
    • TABLE 53: UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S., BY MANUFACTURER, 2016-2017 (UNITS PER MILLION/%)
    • TABLE 54: ESTIMATED INFLUENZA VACCINE SALES DISTRIBUTION IN EU, BY COUNTRY, 2016-2017 (%)
    • TABLE 55: EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
    • TABLE 56: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013-2016 (%)
    • TABLE 57: MARKETED THERAPIES, BY COMPANY, 2016
    • TABLE 58: GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS
    • TABLE 59: CLINICAL TRIALS FOR INFLUENZA THERAPEUTICS, BY SELECTED COUNTRY AND TRIAL STATUS
    • TABLE 60: AMARILLO BIOSCIENCES INFLUENZA TREATMENT PIPELINE
    • TABLE 61: ASTRAZENECA INFLUENZA TREATMENT PIPELINE
    • TABLE 62: GENENTECH INFLUENZA TREATMENT PIPELINE
    • TABLE 63: GLAXOSMITHKLINE INFLUENZA TREATMENT PIPELINE
    • TABLE 64: HEMISPHERX BIOPHARMA INFLUENZA TREATMENT PIPELINE
    • TABLE 65: IL-YANG INFLUENZA TREATMENT PIPELINE
    • TABLE 66: JANSSEN PHARMACEUTICAL CO. INFLUENZA TREATMENT PIPELINE
    • TABLE 67: MATERIA MEDICA INFLUENZA TREATMENT PIPELINE
    • TABLE 68: ROMARK LABORATORIES INFLUENZA TREATMENT PIPELINE
    • TABLE 69: SAREPTA THERAPEUTICS INFLUENZA TREATMENT PIPELINE
    • TABLE 70: SHIONOGI INFLUENZA TREATMENT PIPELINE
    • TABLE 71: TOYAMA CHEMICAL INFLUENZA TREATMENT PIPELINE
    • TABLE 72: VISTERRA INFLUENZA TREATMENT PIPELINE
    • TABLE 73: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
    • TABLE 74: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 75: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013-2016 (%)
    • TABLE 76: INFLUENZA DIAGNOSTIC
    • TABLE 77: CLINICAL CONSIDERATIONS OF RAPID TESTING DURING HIGH INFLUENZA PREVALENCE
    • TABLE 78: CLINICAL CONSIDERATIONS OF RAPID TESTING DURING LOW INFLUENZA PREVALENCE
    • TABLE 79: SELECTED MARKETED RAPID TEST PRODUCTS, DECEMBER 2016
    • TABLE 80: AVERAGE PRICE OF SELECTED RAPID INFLUENZA TESTS ($)
    • TABLE 81: PROVIDERS OF TEST SERVICES
    • TABLE 82: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
    • TABLE 83: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 84: NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*
    • TABLE 85: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013-2016 (%)
    • TABLE 86: INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS
    • TABLE 87: INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS
    • TABLE 88: INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS
    • TABLE 89: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 90: GLOBAL INFLUENZA MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 91: ALERE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 92: ASTRAZENECA'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 93: BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 94: DANAHER'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 95: DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 96: GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 97: HOLOGIC'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 98: MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 99: MYLAN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 100: ORASURE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 101: QIAGEN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 102: QUIDEL'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 103: ROCHE GROUP'S REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 104: SANOFI'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • TABLE 105: SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* ($ BILLIONS)
    • TABLE 106: CSL LIMITED'S COMPANY REVENUES, 2013-2016* ($ MILLIONS)
    • TABLE 107: APPROVED WHO INFLUENZA CENTERS BY REGION

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 ($ MILLIONS)
    • FIGURE 1: WORLDWIDE INFLUENZA ACTIVITY OCTOBER 2014 - MAY 2015
    • FIGURE 2: WORLDWIDE INFLUENZA ACTIVITY MAY 2015 - SEPTEMBER 2015
    • FIGURE 3: VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)
    • FIGURE 4: RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS ALLERGIC TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES FOR U.S. INFLUENZA SEASON, 2015-2016
    • FIGURE 5: GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)
    • FIGURE 6: GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)
    • FIGURE 7: GLOBAL POPULATION BY SELECTED COUNTRY, 2010- 2020 (MILLIONS)
    • FIGURE 8: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2020 (YEARS)
    • FIGURE 9: WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS, 2003-2016* (NO.)
    • FIGURE 10: APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)
    • FIGURE 11: TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS FOR SELECTED COUNTRIES (MILLION)
    • FIGURE 12: PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2016
    • FIGURE 13: GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
    • FIGURE 14: GLOBAL MARKET FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2016 ($ MILLIONS)
    • FIGURE 15: GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, 2010-2021 ($ MILLIONS)
    • FIGURE 16: DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES, BY REGION, 2016 (%)
    • FIGURE 17: U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2021 ($ MILLIONS)
    • FIGURE 18: ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2017 (MILLIONS)
    • FIGURE 19: EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013 (%)
    • FIGURE 21: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2014 (%)
    • FIGURE 22: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2015 (%)
    • FIGURE 23: GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2016 (%)
    • FIGURE 24: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
    • FIGURE 25: GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, 2010-2021 ($ MILLIONS)
    • FIGURE 26: DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES, BY REGION, 2016 (%)
    • FIGURE 27: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013 (%)
    • FIGURE 28: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2014 (%)
    • FIGURE 29: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2015 (%)
    • FIGURE 30: GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2016 (%)
    • FIGURE 31: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, 2010-2021 ($ MILLIONS)
    • FIGURE 32: DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY PRODUCT CLASSIFICATION, 2016 (%)
    • FIGURE 33: DISTRIBUTION OF CONVENTIONAL LABORATORY INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)
    • FIGURE 34: DISTRIBUTION OF RAPID INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)
    • FIGURE 35: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, 2010-2021 ($ MILLIONS)
    • FIGURE 36: DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2016 (%)
    • FIGURE 37: NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*
    • FIGURE 38: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013 (%)
    • FIGURE 39: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2014 (%)
    • FIGURE 40: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2015 (%)
    • FIGURE 41: GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2016 (%)
    • FIGURE 42: GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 ($ MILLIONS)
    • FIGURE 43: DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2016 (%)
    • FIGURE 44: GLOBAL INFLUENZA MARKET, BY REGION, 2010-2021 ($ MILLIONS)
    • FIGURE 45: DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REGION, 2016 (%)
    • FIGURE 46: ALERE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 47: ASTRAZENECA'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 48: BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 49: DANAHER'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 50: DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 51: GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 52: HOLOGIC'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 53: MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 54: MYLAN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 55: ORASURE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 56: QIAGEN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 57: QUIDEL'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 58: ROCHE GROUP'S REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 59: SANOFI'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
    • FIGURE 60: SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* ($ BILLIONS)
    • FIGURE 61: CSL LIMITED'S COMPANY REVENUES, 2013-2016* ($ MILLIONS)
Back to Top